Web & Social Media Analytics Previous Year Question Paper.pdf
Latest Developments in Intravesical Therapy
1. Hugh Mostafid Consultant Urologist North Hampshire Hospital Basingstoke Latest Developments in Intravesical Therapy
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12. BCG Toxicity Spanish CUETO group 53 61 69 Median followup 430 155 500 N 1/3 and 1/6 dose have same toxicity 1/3 dose toxicity lower 1/3 dose toxicity lower Toxicity 1/3 dose is minimum effective dose for int risk 27mg vs. 13.5.mg vs. 30 mg MMC intermediate risk 95.011 2007 1/3 dose as effective as full dose for high risk disease 81mg vs. 27mg in high risk tumours 95.012 2005 No diff in rec. or prog except for multifocal tumours. Trend towards lower RR with full dose in high risk tumours 81mg vs. 27mg BCG Connaught 90.008 2002 Oncological outcome Groups
13.
14.
15.
16.
17.
18. High Risk group G3T1 Multifocal >3 recurrences in 24 months CIS progression side-effects acceptable 1-17 <1-5 46-62 24-38 35 Intermediate Risk Progression Recurrence % of total 6-45 1-17 46-78 24-61 15 High Risk 1-6 <1 31-46 15-24 50 Low Risk 5yr 1yr 5 yr 1 yr
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33. Low Risk group Single TaG1, <3cm Recurrence rate Side effects not justified 1-17 <1-5 46-62 24-38 35 Intermediate Risk Progression Recurrence % of total 6-45 1-17 46-78 24-61 15 High Risk 1-6 <1 31-46 15-24 50 Low Risk 5yr 1yr 5 yr 1 yr
![Intravesical therapy in 2011 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)